SNP-318 is under clinical development by SciNeuro Pharmaceuticals and currently in Phase I for Neurodegenerative Diseases. According to GlobalData, Phase I drugs for Neurodegenerative Diseases have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SNP-318’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SNP-318 overview
SNP-318 is under development for the treatment of restoring vascular health and improving cognition in dementias such as Alzheimer’s disease (AD) and other neurodegenerative diseases. The therapeutic candidate targets targets lipoprotein-associated phospholipase A2 (LP-PLA2). It is administered through oral route.
SciNeuro Pharmaceuticals overview
SciNeuro Pharmaceuticals (SciNeuro) is a clinical-stage biotech company that develops novel medicines for central nervous system (CNS) diseases and neurodegenerative disorders. The company’s pipeline products include SNP318, SNP201, SNP614 and SNP210. Its pipeline of novel therapeutics treats Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). The company also includes human genetics, pharmacology and delivering transformative medicine for diseases of the central nervous system. SciNeuro is headquartered in Rockville, Maryland, the US.
For a complete picture of SNP-318’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
